Table 2.
Univariate and multivariate analyses of factors associated with hepatocellular carcinoma in all patients
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
|
|
|
|||
| Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value | |
| Age (year) | 1.036 (1.025-1.046) | 0.006 | 1.038 (1.027-1.050) | < 0.001 |
| Sex, male vs. female | 1.254 (0.925-1.700) | 0.146 | 1.590 (1.166-2.167) | 0.003 |
| HBeAg, yes vs. no | 1.045 (0.775-1.408) | 0.773 | ||
| Decompensation, yes vs. no | 2.287 (1.709-3.059) | < 0.001 | 1.605 (1.094-2.34) | 0.015 |
| NA-naïve, yes vs. no | 0.928 (0.656-1.312) | 0.672 | ||
| TDF vs. entecavir | 0.585 (0.425-0.806) | 0.001 | 0.672 (0.485-0.930) | 0.017 |
| Diabetes mellitus, yes vs. no | 1.589 (1.201-2.104) | 0.001 | 1.340 (1.010-1.777) | 0.042 |
| Hypertension, yes vs. no | 1.634 (1.259-2.122) | < 0.001 | ||
| HBV DNA, per log10 IU/mL | 1.021 (0.939-1.110) | 0.629 | ||
| AST, per U/L | 1.000 (0.999-1.000) | 0.647 | ||
| ALT, per U/L | 1.000 (0.999-1.000) | 0.256 | ||
| Total bilirubin, per mg/dL | 1.005 (0.971-1.040) | 0.786 | ||
| Albumin, per g/L | 0.553 (0.459-0.666) | < 0.001 | 0.755 (0.592-0.962) | 0.023 |
| INR, per ratio | 1.432 (0.969-2.116) | 0.071 | ||
| eGFR, mL/min/1.73 m2 | 0.991 (0.987-0.996) | < 0.001 | ||
| Platelet, per 103/μL | 0.993 (0.991-0.996) | < 0.001 | 0.996 (0.994-0.999) | 0.008 |
| AFP at baseline, per ng/mL | 1.000 (0.999-1.001) | 0.994 | ||
| Child-Pugh score | 1.164 (1.087-1.248) | < 0.001 | ||
| FIB-4 | 1.051 (1.035-1.068) | < 0.001 | ||
| APRI | 1.006 (0.989-1.023) | 0.514 | ||
AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.